Holen Sie sich die Stockscreener-App
5.03
9.83%
0.45
Handel nachbörslich:
5.10
0.07
+1.39%
Schlusskurs vom Vortag:
$4.58
Offen:
$4.6
24-Stunden-Volumen:
1.40M
Relative Volume:
1.08
Marktkapitalisierung:
$342.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.20M
KGV:
-2.3395
EPS:
-2.15
Netto-Cashflow:
$57,000
1W Leistung:
+34.13%
1M Leistung:
+164.74%
6M Leistung:
+272.59%
1J Leistung:
+168.98%
1-Tages-Spanne:
$4.5808
$5.19
1-Wochen-Bereich:
$3.46
$5.19
52-Wochen-Spanne:
$1.05
$5.19
Climb Bio Inc Stock (CLYM) Company Profile
Firmenname
Climb Bio Inc
Sektor
Branche
Telefon
1-866-857-2596
Adresse
20 WILLIAM STREET, WELLESLEY HILLS
Vergleichen Sie CLYM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
5.03 | 312.28M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Eingeleitet | William Blair | Outperform |
| 2025-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-08-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-06-06 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
Can Climb Bio Inc. stock deliver sustainable ROEMarket Trend Review & Weekly Top Gainers Trade List - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Halozyme (HALO) - The Globe and Mail
Climb Bio’s CLYM116 Moves Into First-in-Human Testing: What Early Investors Should Watch - TipRanks
Climb Bio initiated with a buy at Freedom Capital - MSN
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 - Sahm
Is Climb Bio Inc. stock oversold or undervaluedProfit Target & Low Risk High Reward Ideas - ulpravda.ru
Analyst Downgrade: Can Climb Bio Inc. stock maintain growth trajectoryJuly 2025 Summary & Low Risk Growth Stock Ideas - ulpravda.ru
How Climb Bio Inc. stock reacts to oil pricesTreasury Yields & Free Weekly Watchlist of Top Performers - ulpravda.ru
Climb Bio advances clinical trials with first patients dosed in key studies - Investing.com Australia
Climb Bio outlines 2026 clinical milestones and cash runway - TipRanks
Climb Bio advances clinical trials with first patients dosed in key studies By Investing.com - Investing.com South Africa
Pasadena Star-News: Local News, Sports, Things to DoClimb Bio, Inc.Common Stock (Nasdaq:CLYM) Stock Quote - FinancialContent
Climb Bio reports inducement grant under Nasdaq listing rule - MSN
Climb Bio, Inc.Common Stock (NQ: CLYM - markets.financialcontent.com
Climb Bio (CLYM) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Climb Bio Inc Stock Analysis and ForecastSector Performance Review & Explosive Capital Growth Plans - Early Times
Setup Watch: Will SBUX stock benefit from commodity pricesPortfolio Value Summary & AI Driven Price Forecasts - moha.gov.vn
Alumis issues breach notice to Climb Bio over $3 million milestone payment - Investing.com Nigeria
Climb Bio appoints Edgar D. Charles as Chief Medical Officer - MSN
Alumis IncCo & Its Unit Issues Notice Of Material Breach & Notification Of Claim For Indemnification To Climb BioSEC Filing - TradingView — Track All Markets
Alumis issues breach notice to Climb Bio over $3 million milestone payment By Investing.com - Investing.com South Africa
Alumis Inc. Issues Notice of Material Breach to Climb Bio - TradingView — Track All Markets
Climb Bio challenges Alumis milestone and royalty obligations - MSN
HC Wainwright forecasts 2026 data readouts for Climb Bio’s (CLYM) Budoprutug across clinical tracks - MSN
Climb Bio files complaint against Alumis and AcelyrinSEC filing - MarketScreener
Climb Bio Challenges Alumis Milestone and Royalty Obligations - TipRanks
Climb Bio, Inc. Files Legal Complaint Over Asset Purchase Agreement - TradingView — Track All Markets
H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio’s (CLYM) Budoprutug Across Clinical Tracks - Insider Monkey
Freedom Capital Markets initiates Buy rating on Climb Bio stock with $9 target - Investing.com Canada
Climb Bio initiated with a Buy at Freedom Capital - TipRanks
Apollo Tyres Limited Stock Poised for Technical ComebackTrading Psychology Tips & Outstanding Investment Portfolio - bollywoodhelpline.com
10 Best Biotech Penny Stocks to Buy According to Analysts - Insider Monkey
Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation - Yahoo Finance
Climb Bio price target raised to $11 from $9 at HC Wainwright - MSN
Retail investors in Climb Bio, Inc. (NASDAQ:CLYM) are its biggest bettors, and their bets paid off as stock gained 15% last week - simplywall.st
Vilin Bio Med Limited Breaks Losing Streak — Is the Trend ReversingStock Split Announcements & Rapid Wealth Accumulation - bollywoodhelpline.com
AI Indicators Detect Buy Opportunity in Shree OSFM ESupport and Resistance Levels & Build a Smarter Portfolio Right Now - bollywoodhelpline.com
Candlestick Signal Suggests Reversal in Rajputana Industries LimitedTechnical Resistance Breaks & Accelerated Capital Growth - bollywoodhelpline.com
HC Wainwright Reduces Earnings Estimates for Climb Bio - MarketBeat
Climb Bio Earnings Notes - Trefis
Climb Bio Inc. (CLYM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why analysts upgrade Climb Bio Inc. stockMarket Sentiment Report & Technical Pattern Based Buy Signals - DonanımHaber
Climb Bio, Inc. (NASDAQ:CLYM) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
H.C. Wainwright raises Climb Bio stock price target to $11 on budoprutug progress - Investing.com Canada
Pre Market Movers: ALGS, PDSB, PCSA Swing Big - RTTNews
HC Wainwright & Co. Raises Climb Bio (CLYM) Price Target to $11. - GuruFocus
HC Wainwright & Co. Maintains Climb Bio (CLYM) Buy Recommendation - Nasdaq
Climb Bio price target raised to $11 from $9 at H.C. Wainwright - TipRanks
Climb Bio, Inc. (NASDAQ:CLYM) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ra Capital Management, L.P. Buys 101,462 Shares of Climb Bio (NASDAQ:CLYM) Stock - Defense World
Climb Bio Stock 7-Day Winning Spree: Stock Climbs 169% - Trefis
Finanzdaten der Climb Bio Inc-Aktie (CLYM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):